Literature DB >> 20512933

A novel intracellular isoform of VEGFR-1 activates Src and promotes cell invasion in MDA-MB-231 breast cancer cells.

Belén Mezquita1, Jovita Mezquita, Montserrat Pau, Cristóbal Mezquita.   

Abstract

Two types of VEGFR-1 receptors have been characterized: a full-length transmembrane receptor and a truncated extracellular soluble isoform (sVEGFR-1). We report here the characterization, in normal and cancer cells, of a new family of intracellular isoforms of VEGFR-1 resulting from alternative initiation of transcription in intronic sequences of the gene. While the classical isoforms of VEGFR-1 were barely detectable in MDA-MB-231 breast cancer cells, one of the intracellular isoforms transcribed from intron 21 (i(21)VEGFR-1) was the main isoform expressed in these cells. The new transcript encodes for a protein that contains only the phosphotransferase domain and the carboxyterminal tail of VEGFR-1. Treatment of MDA-MB-231 cells with siRNA specific for the tyrosine domain of VEGFR-1 suppressed the expression of i(21)VEGFR-1, downregulated phosphorylation of Src at tyrosine 418, and reduced markedly the invasion capacity of these cells in vitro. Accordingly, overexpression of transfected i(21)VEGFR-1 in MDA-MB-231 cells upregulated the active form of Src and increased invasiveness of MDA-MB-231 cells. The expression of i(21)VEGFR-1 in MDA-MB-231 cells was inhibited by retinoic acid. Both, activation of Src and downregulation by retinoic acid, have been reported in other intracellular members of the Fms/Kit/PDGFR family of tyrosine kinases, particularly in the intracellular isoform of c-kit, analogous structurally to i(21)VEGFR-1 and frequently expressed in cancer cells. (c) 2010 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20512933     DOI: 10.1002/jcb.22584

Source DB:  PubMed          Journal:  J Cell Biochem        ISSN: 0730-2312            Impact factor:   4.429


  11 in total

1.  A randomized phase II study of cediranib alone versus cediranib in combination with dasatinib in docetaxel resistant, castration resistant prostate cancer patients.

Authors:  Anna Spreafico; Kim N Chi; Srikala S Sridhar; David C Smith; Michael A Carducci; Peter Kavsak; Tracy S Wong; Lisa Wang; S Percy Ivy; Som Dave Mukherjee; Christian K Kollmannsberger; Mahadeo A Sukhai; Naoko Takebe; Suzanne Kamel-Reid; Lillian L Siu; Sebastien J Hotte
Journal:  Invest New Drugs       Date:  2014-05-03       Impact factor: 3.850

2.  Protein kinase C regulates FLT1 abundance and stimulates its cleavage in vascular endothelial cells with the release of a soluble PlGF/VEGF antagonist.

Authors:  Nandita S Raikwar; Kang Z Liu; Christie P Thomas
Journal:  Exp Cell Res       Date:  2013-07-30       Impact factor: 3.905

3.  Integrative genomic analysis of matched primary and metastatic pediatric osteosarcoma.

Authors:  Gian Luca Negri; Bruno M Grande; Alberto Delaidelli; Amal El-Naggar; Dawn Cochrane; Ching C Lau; Timothy J Triche; Richard A Moore; Steven Jm Jones; Alexandre Montpetit; Marco A Marra; David Malkin; Ryan D Morin; Poul H Sorensen
Journal:  J Pathol       Date:  2019-08-28       Impact factor: 9.883

Review 4.  Regulation of the Ras-MAPK and PI3K-mTOR Signalling Pathways by Alternative Splicing in Cancer.

Authors:  Zahava Siegfried; Serena Bonomi; Claudia Ghigna; Rotem Karni
Journal:  Int J Cell Biol       Date:  2013-09-03

5.  Tumour cells expressing single VEGF isoforms display distinct growth, survival and migration characteristics.

Authors:  Chryso Kanthou; Gabi U Dachs; Diane V Lefley; Andrew J Steele; Claudia Coralli-Foxon; Sheila Harris; Olga Greco; Sofia A Dos Santos; Constantino C Reyes-Aldasoro; William R English; Gillian M Tozer
Journal:  PLoS One       Date:  2014-08-13       Impact factor: 3.240

6.  Aberrations in Angiogenic Signaling and MYC Amplifications are Distinguishing Features of Angiosarcoma.

Authors:  Vittal Kurisetty; Brad A Bryan
Journal:  Angiol Open Access       Date:  2013-04-08

7.  Loss of membranous VEGFR1 expression is associated with an adverse phenotype and shortened survival in breast cancer.

Authors:  Patrick Lebok; Julia Huber; Eike-Christian Burandt; Annette Lebeau; Andreas Holger Marx; Luigi Terracciano; Uwe Heilenkötter; Fritz Jänicke; Volkmar Müller; Peter Paluchowski; Stefan Geist; Christian Wilke; Ronald Simon; Guido Sauter; Alexander Quaas
Journal:  Mol Med Rep       Date:  2016-06-23       Impact factor: 2.952

8.  Unlocking Doors without Keys: Activation of Src by Truncated C-terminal Intracellular Receptor Tyrosine Kinases Lacking Tyrosine Kinase Activity.

Authors:  Belén Mezquita; Pau Mezquita; Montserrat Pau; Jovita Mezquita; Cristóbal Mezquita
Journal:  Cells       Date:  2014-02-14       Impact factor: 6.600

9.  Phosphatidylserine-selective targeting and anticancer effects of SapC-DOPS nanovesicles on brain tumors.

Authors:  Víctor M Blanco; Zhengtao Chu; Subrahmanya D Vallabhapurapu; Mahaboob K Sulaiman; Ady Kendler; Olivier Rixe; Ronald E Warnick; Robert S Franco; Xiaoyang Qi
Journal:  Oncotarget       Date:  2014-08-30

10.  All-trans-retinoic acid activates the pro-invasive Src-YAP-Interleukin 6 axis in triple-negative MDA-MB-231 breast cancer cells while cerivastatin reverses this action.

Authors:  Belén Mezquita; Pau Mezquita; Montserrat Pau; Laura Gasa; Lourdes Navarro; Mireia Samitier; Miquel Pons; Cristóbal Mezquita
Journal:  Sci Rep       Date:  2018-05-04       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.